Subscribe or Manage Preferences

Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA

Rheumatology Practice Management December 2017 Vol 5 No 6 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

 

A previous study reported that highly sensitive cardiac troponin I (cTnI; >1.5 pg/mL) was an independent predictor of occult coronary plaque burden and composition on coronary computed tomography angiography (CTA) in patients with established rheumatoid arthritis (RA). The current study examines whether high cTnI also predicts incident long-term cardiovascular (CV) events and optimizes CV risk stratification in the Prospective Evaluation of Lateral Coronary Atherosclerosis in RA (PROTECT-RA) trial after 5 years of follow-up.

Eligible patients with RA (n = 159) without symptoms or prior diagnosis of CV disease underwent a baseline 64-slice CTA for plaque evaluation; blood was also collected for laboratory evaluations, including for biomarker assessments. Patients were followed for a mean of 60 ± 26 months for incident CV events. Using Cox regression analysis, the association between high cTnI (>1.5 pg/mL) and CV events was evaluated.

During the 5-year follow-up period, 11 patients suffered incident events (1.54/100 patient-years). Of these, 8 were ischemic CV events, including 1 cardiac death, 3 myocardial infarctions, 2 strokes, and 2 peripheral arterial ischemic events requiring emergent revascularizations; and 3 were nonischemic events, including new onset, hospitalization, and systolic heart failure.

The CV cohort showed an increased number of traditional CV risk factors, including diabetes (4/11 patients), hypertension (8/11 patients), and D’Agostino Framingham score (15.6). The CV cohort also showed unfavorable coronary plaque burden and associated biomarkers, including coronary artery calcium, segment involvement score, segment stenosis score, plaque burden score, and mixed plaque score.

Patients who experienced CV events had higher levels of highly sensitive cTnI compared with those who did not (2.6 [2.1-4.4] pg/mL vs 1.5 [1.0-2.6] pg/mL; P <.01). Measurement of highly sensitive cTnI was higher in patients with plaque versus those without. Coronary plaque presence, burden, and complexity were enriched in patients with higher levels of highly sensitive cTnI. Importantly, higher levels of highly sensitive cTnI predicted the risk for incident CV events independently of demographic and traditional cardiac risk factors, including age, sex, hypertension, diabetes, dyslipidemia, smoking, body mass index, and prednisone use. Moreover, patients with low cTnI (<1.5 pg/mL) were found to be 82% less likely to suffer a CV event.

Source: Karpouzas G, Estis J, Pham L, et al. Highly sensitive cardiac troponin-I in peripheral blood predicts cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 867.

Related Items
Efficacy and Safety of Switching from Adalimumab to Sarilumab
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab Efficacy Maintained or Improved in Previously Treated Patients with RA
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Tofacitinib with and without MTX and Adalimumab with MTX Improves PROs in Patients with RA
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: February 26, 2018
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search